Six‐year multi‐centre, observational, post‐marketing surveillance of the safety of the HPV‐16/18 AS04‐adjuvanted vaccine in women aged 10–25 years in Korea

To evaluate the safety of HPV‐16/18 AS04‐adjuvanted vaccine when administered as per the PI in Korea.

• Publication year

  2017

• Venue

  Pharmacoepidemiology and Drug Safety

• Publication date

  2017-03-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pds.4175PMID 28266092PMCID 5516175
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Six‐year multi‐centre, observational, post‐marketing surveillance of the safety of the HPV‐16/18 AS04‐adjuvanted vaccine in women aged 10–25 years in Korea

  2017cited by this paper
• Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination

  2015cited by this paper
• Prophylactic HPV vaccination: past, present, and future

  2015cited by this paper
• Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

  2015cited by this paper
• HPV vaccination crisis in Japan.

  2015cited by this paper
• Safety of human papillomavirus vaccines: a review

  2015cited by this paper
• Health behaviors and related demographic factors among Korean adolescents.

  2014cited by this paper
• Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

  2014cited by this paper
• Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience

  2014cited by this paper
• Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6–year follow-up study

  2014cited by this paper
• Tracking the global spread of vaccine sentiments: The global response to Japan's suspension of its HPV vaccine recommendation

  2014cited by this paper
• Long-term Immunogenicity and Safety of the HPV-16/18 AS04-adjuvanted Vaccine in 10- to 14-year-old Girls: Open 6-year Follow-up of an Initial Observer-blinded, Randomized Trial

  2014cited by this paper
• Comprehensive control of human papillomavirus infections and related diseases.

  2013cited by this paper
• Safety of Human Papillomavirus Vaccines: A Review

  2013cited by this paper
• Comprehensive control of human papillomavirus infections and related diseases.

  2013cited by this paper
• Comprehensive control of human papillomavirus infections and related diseases.

  2013cited by this paper
• Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands.

  2011cited by this paper
• Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women

  2011cited by this paper
• Immunogenicity and Safety of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine Administered According to an Alternative Dosing Schedule Compared With the Standard Dosing Schedule in Healthy Women Aged 15 to 25 Years: Results From a Randomized Study

  2011cited by this paper
• Safety and tolerability of bivalent HPV vaccine: An Italian post-licensure study

  2011cited by this paper
• Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

  2011cited by this paper
• Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years

  2010cited by this paper
• Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls.

  2010cited by this paper
• Efficacy of Human Papillomavirus Type 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years: Final Analysis of a Phase 2 Double-Blind, Randomized Controlled Trial

  2010cited by this paper
• Efficacy of Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Japanese Women Aged 20 to 25 Years: Interim Analysis of a Phase 2 Double-Blind, Randomized, Controlled Trial

  2010cited by this paper
• Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years.

  2009cited by this paper
• Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years.

  2009cited by this paper
• Scientific conclusions

  2009cited by this paper
• Current status of cervical cancer and HPV infection in Korea.

  2009cited by this paper
• Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

  2009cited by this paper
• Acquisition of new infection and clearance of type-specific human papillomavirus infections in female students in Busan, South Korea: a follow-up study

  2008cited by this paper
• Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

  2007cited by this paper
• The carcinogenicity of human papillomavirus types reflects viral evolution.

  2005cited by this paper
• Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea.

  2004cited by this paper
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

  1999cited by this paper
• The Netherlands Source: Cbs/cheps Higher Education Monitor

  year unknowncited by this paper

• Serious adverse events following human papillomavirus vaccination: A systematic review and meta-analysis of post-marketing evidence.

  2026cites this paper
• Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)

  2023cites this paper
• Association between human papillomavirus vaccination and serious adverse events in South Korean adolescent girls: nationwide cohort study

  2021cites this paper
• Six‐year multi‐centre, observational, post‐marketing surveillance of the safety of the HPV‐16/18 AS04‐adjuvanted vaccine in women aged 10–25 years in Korea

  2017cites this paper